Skip to content

Efficiency and effects of segmental rapid molar distalization versus sequential staging in Class II malocclusion treatment using Invisalign: a randomized prospective clinical trial

Efficiency and effects of segmental rapid molar distalization versus sequential staging in Class II malocclusion treatment using Invisalign: a randomized prospective clinical trial

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089256
Enrollment
Unknown
Registered
2024-09-04
Start date
2024-09-08
Completion date
Unknown
Last updated
2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Class II malocclusion

Interventions

Experimental group :rapid molar distalization
Control group:sequential molar distalization

Sponsors

Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1) Age:18-35 years old 2) Permanent dentition 3) Class II molar relationship 4) the distance of molardistalization: 2mm-4mm 5) ANB angle between 2 and 7° 6) MP-FH angle between 32-37° 7) Patients who can understand and cooperate in completing treatment, voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1) Patients who required functional appliance therapy 2) Patients with moderate to severe periodontal disease 3) Patients with temporomandibular joint disease 4) Craniofacial syndromes or cleft lip and palate 5) Excluding diseases that seriously affect bone metabolism

Design outcomes

Primary

MeasureTime frame
The ratio of the actual space to the designed space ;

Secondary

MeasureTime frame
proclination of upper incisors relative to anterior cranial base plane;the duration of molar distalization;

Countries

China

Contacts

Public ContactChu Fengting

Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine

quci2001@163.com+86 159 0178 0833

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026